1. Docosahexaenoic acid and disulfiram act in concert to kill cancer cells: a mutual enhancement of their anticancer actions
   Yang Jiao et al, 2017, Oncotarget CrossRef
2. STON2 negatively modulates stem-like properties in ovarian cancer cells via DNMT1/MUC1 pathway
   Shanshan Xu et al, 2018, Journal of Experimental & Clinical Cancer Research CrossRef
3. Cancer Stem Cells in Ovarian Cancer—A Source of Tumor Success and a Challenging Target for Novel Therapies
   Jacek R Wilczyński et al, 2022, International Journal of Molecular Sciences CrossRef
4. Presence and role of stem cells in ovarian cancer
   Natasa Kenda Suster et al, 2019, World Journal of Stem Cells CrossRef
5. Blocking CD47-SIRPα Signal Axis as Promising Immunotherapy in Ovarian Cancer
   Xukai Luo et al, 2023, Cancer Control CrossRef
6. Downregulation of transient receptor potential cation channel, subfamily C, member 1 contributes to drug resistance and high histological grade in ovarian cancer
   XIA LIU et al, 2016, International Journal of Oncology CrossRef
7. Spheres from cervical cancer cells display stemness and cancer drug resistance
   Huan Liu et al, 2016, Oncology Letters CrossRef
8. Cyclooxygenase-1 (COX-1) and COX-1 Inhibitors in Cancer: A Review of Oncology and Medicinal Chemistry Literature
   Alessandra Pannunzio et al, 2018, Pharmaceuticals CrossRef
9. The mitochondrial landscape of ovarian cancer: emerging insights
   Pallavi Shukla et al, 2021, Carcinogenesis CrossRef
10. MTUS1 , a gene encoding angiotensin-II type 2 (AT2) receptor-interacting proteins, in health and disease, with special emphasis on its role in carcinogenesis
    Ibrahim Bozgeyik et al, 2017, Gene CrossRef
11. The transcriptional co-activator NCOA6 promotes estrogen-induced GREB1 transcription by recruiting ERα and enhancing enhancer–promoter interactions
    Zhangwei Tong et al, 2019, Journal of Biological Chemistry CrossRef
12. Thalidomide inhibits proliferation and epithelial‑mesenchymal transition by modulating CD133 expression in pancreatic cancer cells
    Congying Chen et al, 2017, Oncology Letters CrossRef
13. Mithramycin A sensitizes therapy-resistant breast cancer stem cells toward genotoxic drug doxorubicin
    Shilpi Saha et al, 2015, Translational Research CrossRef
14. The Krüppel-like factors in female reproductive system pathologies
    Rosalia C M Simmen et al, 2015, Journal of Molecular Endocrinology CrossRef
15. Cancer Stem Cells: An Ever-Hiding Foe
    Jacek R. Wilczyński, 2022, Interaction of Immune and Cancer Cells CrossRef
16. CD47 promotes ovarian cancer progression by inhibiting macrophage phagocytosis
    Ran Liu et al, 2017, Oncotarget CrossRef
17. CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide
    Richard E. Kast et al, 2014, Oncotarget CrossRef
18. CD47—a novel prognostic predicator in epithelial ovarian cancer and correlations with clinicopathological and gene mutation features
    Xukai Luo et al, 2024, World Journal of Surgical Oncology CrossRef
19. Consideration of GREB1 as a potential therapeutic target for hormone-responsive or endocrine-resistant cancers
    Kendra M Hodgkinson et al, 2014, Expert Opinion on Therapeutic Targets CrossRef